A Baby Step Backwards

Bringing the Tools of Accountable Care to Maternity Care is a Great Idea – But This Sure Ain’t It By VICTORIA ADEWALE & J.D. KLEINKE How desperate are we to find some kind of good news about the sorry state of maternity care in America? To find out, look no further than the current cover…

Read More

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder. The post AstraZeneca Turns to CSPC…

Read More

AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for Oral Way to Drug Lp(a)

Cardiovascular disease drugs in development intended to reduce lipoprotein (a) are mostly injectable medications, though Eli Lilly also has both oral and injectable drugs in the clinic. AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group. The post AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for…

Read More

Changing COVID-19 Booster Policies and Florida’s Decision to End Vaccine Mandates Create Confusion — The Monitor

This volume explores confusion around COVID-19 booster eligibility as federal recommendations shift and conflicts with guidance from physician organizations; Florida’s decision to end school vaccine mandates; and research demonstrating that artificial intelligence chatbots can provide generally sound advice, but struggle to make personalized recommendations.

Read More